Abstract. IMP3 is an RNA binding protein required for ribosomal RNA processing, which has been suggested to be a prognostic marker in a large variety of human types of cancer. However, available data on the prevalence of IMP3 expression are largely discrepant. To systematically investigate the epidemiology and clinical relevance of IMP3 expression in human cancers we employed a two-step tissue microarrays (TMAs) approach. First, a normal tissue TMA and a multi-tumor TMA were analyzed for immunohistochemically detectable expression of IMP3 in 76 different normal tissue types and 3889 cancer samples from 95 different tumor categories. In a second step, we searched for associations between IMP3 expression and tumor phenotype and patient prognosis in TMAs containing 697 urinary bladder cancers, 1711 colon cancers, 343 esophageal adenocarcinomas, 251 esophageal squamous cell cancers, 673 lung cancers), 275 pancreatic cancers and 230 stomach cancers. In normal tissues, unequivocal IMP3 expression was found in placenta, lymphocytes and some types of glandular epithelial cells. In cancers, at least one case with weak expression could be found in 76 out of 95 (80%) different tumor types and 64 entities (67%) had at least one tumor with strong positivity. IMP3 expression was most frequently found in testicular cancer (including 71% seminomas and 96% non-seminomas), neuroblastoma (88%), and squamous cell cancer of various origins. Significant associations were found between IMP3 and adverse tumor features in esophageal adenocarcinomas and cancers of the urinary bladder, lung, stomach, and pancreas. In summary, IMP3 was frequently expressed in many different tumor types, and was typically associated with aggressive tumor features.

Introduction

Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP family playing an important role in cell migration in early embryogenesis (1,2). This ‘U3 small nucleolar ribonucleoprotein’ is a component of an RNA binding protein required for the early cleavage during pre-18s ribosomal RNA processing. Previously, IMP3 has gained considerable interest as a cancer-associated protein. IMP3 overexpression has been reported in a variety of human types of cancer, including lung cancer (3), germ cell cancer (4), colon cancer (5), pancreatic cancer (6), gastric cancer (7), liver cancer (8), and kidney cancer (9), and has been linked to advanced disease stage and adverse clinical outcome in some of these cancers (5,7,8,10-12). Collectively, these studies strongly suggest that IMP3 may represent a valuable prognostic marker in human cancer. However, as the number of studies suggesting biological and clinical relevance of IMP3 is rapidly increasing, there are also a growing number of reports revealing considerable discrepancies with respect to the frequency of expression in various types of cancer. For example, reported frequencies in IMP3 expression ranges from 0 to 83% in prostate cancer (13-16), from 11 to 86% in papillary thyroid cancer (17-20), from 11 to 65% in papillary renal cell cancer (9,12), from 0 to 52% in leiomyoma (21,22), from 21 to 71% in invasive urinary bladder tumor (23,24), from 50 to 100% in small cell lung cancer (3,25), and from 37 to 83% in malignant mesothelioma (26,27). Such discrepancies may be due to the use of different antibodies, staining protocols, and scoring criteria in these studies. The optimal study for assessing the relative importance of a potentially relevant molecule across tumor types includes the analysis of as large a number of different normal tissues, cancer types and subtypes as possible, followed by the evaluation of the clinical value of IMP3 in selected types of cancer with
frequent IMP3 expression. Moreover, it would be necessary to ensure a maximal standardization of all these analyses. Tissue microarray (TMA) technology is a suitable tool for such a study, as a large number of tissues can be analyzed on few sections that are cut in 1 day and that can be stained in 1 day in a set of reagents under completely identical staining conditions.

In this study, we utilized a two-step tissue microarray (TMA) approach to evaluate the clinical utility of IMP3 testing in human normal tissues and cancer. In a first step, we screened 76 different normal tissue types and samples of 95 different tumor types using a multi-tumor TMA. In a second step, tumor-type specific TMAs with clinical follow-up data were utilized to evaluate the clinical significance of IMP3 alterations in five selected tumor entities. Our approach implicated frequent IMP3 expression in 76 different tumor types and concomitantly demonstrated the association between IMP3 expression and poor prognosis in adenocarcinomas of the lung.

Materials and methods

Human tissues. The construction of tissue microarrays was as previously described (28). The normal tissue TMA was composed of 8 samples each of 76 different normal tissue types (608 samples on one slide). The multi-tumor TMA contained 3,899 primary tumors from 95 different tumor types and subtypes distributed among 10 different TMA blocks each containing between 350 and 680 samples. The exact composition of this TMA is presented in Table I. In addition, six different prognosis TMAs were analyzed, representing 697 urinary bladder cancers (694 with clinical follow-up data), 1711 colorectal cancers (1709 with clinical follow-up data), 343 esophageal adenocarcinomas (300 with clinical follow-up data), 251 esophageal squamous cell cancers (244 with clinical follow-up data), 673 lung cancers (269 with clinical follow-up data), 275 pancreatic cancers (219 with clinical follow-up data), and 230 stomach cancers (146 with clinical follow-up data). The composition of these TMAs has been described before (29-33). No informed consent was obtained in accordance with the local law (HmbKHG, §12.1).

Immunohistochemistry. Freshly cut TMA sections were analyzed. IMP3 expression was detected with a monoclonal mouse anti-human antibody (clone 69.1; Dako M3626, Glostrup, Denmark) in a dilution of 1:100 after peroxidase blocking with H2O2 (Dako S2023) for 10 min. High-temperature pretreatment of slides was carried out in an autoclave with citrate buffer, pH 9.0 for 5 min. The Envision system (Dako 5007) was used to visualize the staining. In normal tissues, a cell type specific distribution of IMP3 expression was recorded, and the staining intensity was estimated as weak (+), moderate (++), or strong (+++). In tumor tissues, cytoplasmic staining was evaluated by staining intensity (0, 1+, 2+, and 3+) and the fraction of positive tumor cells was scored for each tissue spot. A final score was built from these two parameters according to the following criteria: negative scores had a staining intensity of 0 and 1+ in ≤10% of tumor cells; weak scores had a staining intensity of 1+ in >10% and ≤70% of tumor cells or a staining intensity of 2+ in ≤30% of tumor cells; and strong scores had a staining intensity of 2+ in >70% of tumor cells or a staining intensity of 3+ in >30% of tumor cells. All tumors exhibiting at least weak expression were defined as IMP3-positive.

Statistical analysis. For statistics, JMP® 12.0 software (SAS Institute Inc., Cary, NC, USA) was used. All P-values were two-sided, and P-values <0.05 were considered as significant. To study the relationship between IMP3 expression and clinicopathological parameters, contingency table analysis and Chi-square test (likelihood) were used. Analysis on recurrence-free and overall survival was performed using the Kaplan-Meier method and was compared via log-rank test. Cox regression and multivariate analyses were used to assess independence of IMP3 staining.

Results

IMP3 protein expression in normal tissues. Positive IMP3 staining was seen in few normal tissues and in specific cell types only, including amnion (+), chorion cells (+) syncytiotrophoblast (+++), cytotrophoblast (+++, decidua (+) and mesenchymal cells (++) of the placenta, lymph follicles in lymph nodes and tonsils (lymphoblasts (+++), lymphocytes (+++), thymocytes (+), absorptive cells of the ileum (+++), crypt cells of rectal mucosa (+), mucus cells (+) of submucosal and sublingual glands, spermatogonia of the testis (++), ciliated cells (+) of bronchial mucosa, mucin cells of bronchial glands (+++), secretory cells of the endocervix (+), ciliated cells of the fallopian tube (+++), and cells of the adenohypophysis of the anterior lobe of the pituitary gland (+).

Normal tissue samples that were also analyzed but did not exhibit any IMP3 staining included: aorta, heart, striated muscle, tongue, uterus, appendix, esophagus, stomach, ileum, muscle, colon, kidney, urinary bladder, penis, ovary, fat, skin, lip, oral cavity, anal canal, ecotocervix, spleen, duodenum, gallbladder, liver, pancreas, parotid gland, bone marrow, prostate, seminal vesicles, epididymis, nose sinus, lung, breast, adrenal gland, parathyroid gland, thyroid gland, cerebellum and cerebrum.

IMP3 protein expression in tumors. Analyzable results could be obtained from 96 of the 99 types of cancer represented in our multi-tumor TMA. At least weak IMP3 protein expression could be detected in 76 (80%) of the 95 tumor categories with analyzable results, including 64 (67%) categories where at least one tumor revealed a strong positivity. The immunohistochemical results are summarized in Table I. IMP3 positivity was most striking in testicular cancers, where all examined tumors exhibited positive staining, including 71% (seminomas) and 96% (non-seminomas) with strong staining. Additional cancers with frequent IMP3 positivity included Hodgkin's lymphomas (90%), neuroblastomas (88% positive), squamous cell cancers of various origins, e.g. of the lungs (81%), oral cavity (73%), esophagus (71%), larynx (67%), penis (59%), and skin (50%), as well as adenocarcinomas of the esophagus (74%), pancreas (62%), cervix (58%), stomach (50-55%), and lungs (51%). In contrast, IMP3 staining was only rarely
Table I. Summary of IMP3 immunohistochemical findings in 95 human types of cancer.

| Tumor entity                                      | On TMA (n) | Analyzable\(^a\) (n) | IMP3 IHC results |        |
|--------------------------------------------------|------------|-----------------------|------------------|--------|
|                                                  |            |                       | Negative | Weak | Moderate | Strong |
| **Skin tumors**                                   |            |                       |          |      |          |        |
| Skin, Merkel cell carcinoma                      | 6          | 1                     | 0%       | 100% | 0%       | 0%     |
| Skin, malignant schwannoma                       | 14         | 11                    | 36%      | 0%   | 18%      | 45%    |
| Skin, squamous cell cancer                       | 51         | 40                    | 50%      | 10%  | 20%      | 20%    |
| Skin, malignant melanoma                         | 37         | 26                    | 54%      | 0%   | 8%       | 38%    |
| Pleomorphic sarcoma, NOS                          | 25         | 19                    | 74%      | 0%   | 0%       | 26%    |
| Pilomatrixoma                                     | 48         | 24                    | 75%      | 17%  | 4%       | 4%     |
| Basalioma                                         | 67         | 39                    | 79%      | 8%   | 8%       | 5%     |
| Benign naevus                                     | 59         | 35                    | 97%      | 3%   | 0%       | 0%     |
| Skin, dermatofibrosarcoma protuberans             | 5          | 4                     | 100%     | 0%   | 0%       | 0%     |
| **Lung tumors**                                   |            |                       |          |      |          |        |
| Lung, squamous cell cancer                        | 59         | 37                    | 19%      | 19%  | 14%      | 49%    |
| Larynx, squamous cell cancer                      | 57         | 39                    | 33%      | 31%  | 13%      | 23%    |
| Lung, large cell cancer                           | 48         | 21                    | 43%      | 0%   | 19%      | 38%    |
| Lung, adenocarcinomas                             | 71         | 39                    | 49%      | 18%  | 5%       | 28%    |
| Lung, malignant mesothelioma                      | 28         | 6                     | 50%      | 0%   | 0%       | 50%    |
| Pharynx lymphoepithelial ca.                      | 5          | 4                     | 50%      | 0%   | 0%       | 50%    |
| Lung, small cell lung cancer                      | 15         | 2                     | 50%      | 0%   | 50%      | 0%     |
| Lung bronchioalveolar cancer                      | 15         | 8                     | 63%      | 0%   | 0%       | 38%    |
| **Gynecological tumors**                          |            |                       |          |      |          |        |
| Cervix, adenosquamous ca.                         | 3          | 3                     | 33%      | 33%  | 0%       | 33%    |
| Cervix, squamous cell carcinoma                   | 63         | 58                    | 62%      | 19%  | 5%       | 14%    |
| Cervix, adenocarcinoma                            | 48         | 24                    | 42%      | 21%  | 4%       | 33%    |
| Ovary, mucinous cancer                            | 46         | 32                    | 41%      | 16%  | 6%       | 38%    |
| Ovary, serous cancer                              | 63         | 53                    | 55%      | 9%   | 13%      | 23%    |
| Ovary, mullerian mixed type tumor                 | 38         | 14                    | 57%      | 0%   | 0%       | 43%    |
| Ovary, endometrioid cancer                        | 22         | 18                    | 67%      | 11%  | 11%      | 11%    |
| Uterus endometrial cancer                         | 60         | 43                    | 67%      | 14%  | 5%       | 14%    |
| Vulva, squamous cell cancer                       | 61         | 37                    | 73%      | 16%  | 0%       | 11%    |
| Granular cell tumor                               | 8          | 5                     | 80%      | 20%  | 0%       | 0%     |
| Leiomyosarcoma                                     | 28         | 25                    | 88%      | 0%   | 8%       | 4%     |
| Ovary, Brenner                                    | 45         | 14                    | 93%      | 0%   | 0%       | 7%     |
| Mammary, apocrine type cancer                     | 17         | 3                     | 67%      | 0%   | 0%       | 33%    |
| Mammary, medullary type cancer                    | 64         | 42                    | 76%      | 7%   | 10%      | 7%     |
| Mammary, ductal type cancer                       | 62         | 29                    | 93%      | 3%   | 0%       | 3%     |
| Mammary, lobular type cancer                      | 65         | 23                    | 100%     | 0%   | 0%       | 0%     |
| Mammary, mucinous type cancer                     | 61         | 22                    | 100%     | 0%   | 0%       | 0%     |
| Mammary, tubular type cancer                      | 60         | 17                    | 100%     | 0%   | 0%       | 0%     |
| Mammary, cribriform type cancer                   | 26         | 13                    | 100%     | 0%   | 0%       | 0%     |
| Mammary, phylloid type tumor                      | 48         | 11                    | 100%     | 0%   | 0%       | 0%     |
| Uterus stromasarcoma                              | 13         | 2                     | 100%     | 0%   | 0%       | 0%     |
| Uterus leiomyoma                                  | 27         | 20                    | 100%     | 0%   | 0%       | 0%     |
| **Gastrointestinal tumors and head and neck tumors** |          |                       |          |      |          |        |
| Esophagus, adenocarcinoma                         | 60         | 31                    | 26%      | 29%  | 29%      | 16%    |
| Mouth, squamous cell cancer                       | 54         | 33                    | 27%      | 27%  | 9%       | 36%    |
| Esophagus, squamous cell ca.                      | 60         | 24                    | 29%      | 33%  | 13%      | 25%    |
| Pancreas, adenoca. ampulla                        | 29         | 9                     | 33%      | 33%  | 33%      | 0%     |
| Pancreas, ductal adenocarcinoma                   | 56         | 21                    | 38%      | 29%  | 24%      | 10%    |
| Intestinal cancer                                 | 22         | 7                     | 43%      | 14%  | 14%      | 29%    |
| Stomach, diffuse type cancer                      | 56         | 11                    | 45%      | 36%  | 9%       | 9%     |
| Stomach, intestinal type cancer                   | 62         | 18                    | 50%      | 28%  | 0%       | 22%    |
| Gallbladder cancer                                | 30         | 18                    | 50%      | 28%  | 11%      | 11%    |
| Colon cancer                                      | 60         | 19                    | 53%      | 16%  | 5%       | 26%    |
### Table I. Continued. Summary of IMP3 immunohistochemical findings in 95 human types of cancer.

| Tumor entity                                      | On TMA (n) | Analyzable<sup>a</sup> (n) | IMP3 IHC results |
|--------------------------------------------------|------------|------------------------------|------------------|
|                                                  |            |                              | Negative | Weak | Moderate | Strong |
| Gastrointestinal tumors and head and neck tumors |            |                              |          |      |          |        |
| Anal cancer                                      | 18         | 7                            | 57%      | 29%  | 14%      | 0%     |
| Colon, high grade adenoma                        | 40         | 15                           | 60%      | 33%  | 7%       | 0%     |
| Hepatocellular carcinoma                        | 55         | 23                           | 61%      | 4%   | 4%       | 30%    |
| Warthin tumor                                    | 57         | 39                           | 79%      | 18%  | 3%       | 0%     |
| Parotid gland, mucoepidermoid ca.                | 46         | 16                           | 81%      | 0%   | 0%       | 19%    |
| Colon, low grade adenoma                         | 56         | 19                           | 89%      | 5%   | 0%       | 5%     |
| Basal cell adenoma                               | 37         | 22                           | 95%      | 0%   | 0%       | 5%     |
| GIST                                             | 46         | 40                           | 100%     | 0%   | 0%       | 0%     |
| Parotid gland, pleomorphic adenoma               | 61         | 30                           | 100%     | 0%   | 0%       | 0%     |
| Pancreas, neuroendocrine ca.                     | 20         | 5                            | 100%     | 0%   | 0%       | 0%     |
| Genitourinary tract tumors                       |            |                              |          |      |          |        |
| Testis, seminoma                                 | 92         | 69                           | 0%       | 13%  | 16%      | 71%    |
| Testis, non-seminoma                             | 45         | 25                           | 0%       | 4%   | 0%       | 96%    |
| Teratoma                                         | 60         | 15                           | 13%      | 7%   | 13%      | 67%    |
| Oncocytoma                                       | 62         | 9                            | 33%      | 22%  | 11%      | 33%    |
| Penis, squamous cell cancer                      | 46         | 22                           | 41%      | 18%  | 14%      | 27%    |
| Urinary bladder, T2-T4 tumors                    | 60         | 56                           | 61%      | 11%  | 4%       | 25%    |
| Urinary bladder, Ta-Tumors                       | 62         | 57                           | 98%      | 2%   | 0%       | 0%     |
| Kidney chromophobtic                             | 56         | 9                            | 67%      | 11%  | 0%       | 22%    |
| Kidney, papillary                                | 31         | 8                            | 75%      | 0%   | 0%       | 25%    |
| Kidney, clear cell cancer                        | 68         | 45                           | 96%      | 2%   | 0%       | 2%     |
| Prostate cancer                                  | 63         | 44                           | 100%     | 0%   | 0%       | 0%     |
| Neuroendocrine tumors                            |            |                              |          |      |          |        |
| Adrenal gland carcinoma                          | 8          | 6                            | 83%      | 0%   | 0%       | 17%    |
| Adrenal gland adenoma                            | 21         | 19                           | 89%      | 5%   | 0%       | 5%     |
| Thyroid, anaplastic cancer                       | 3          | 1                            | 0%       | 0%   | 0%       | 100%   |
| Thyroid, medullary cancer                        | 28         | 6                            | 17%      | 0%   | 0%       | 83%    |
| Thyroid, papillary cancer                        | 54         | 15                           | 87%      | 13%  | 0%       | 0%     |
| Thyroid, follicular cancer                       | 47         | 10                           | 90%      | 0%   | 0%       | 10%    |
| Thyroid, adenoma                                 | 65         | 22                           | 91%      | 0%   | 0%       | 9%     |
| Paraganglioma                                    | 36         | 29                           | 93%      | 0%   | 0%       | 7%     |
| Pheochromocytoma                                 | 64         | 48                           | 100%     | 0%   | 0%       | 0%     |
| Nervous system tumors                            |            |                              |          |      |          |        |
| Neuroblastoma                                    | 51         | 26                           | 12%      | 4%   | 8%       | 77%    |
| Astrocytoma                                       | 48         | 6                            | 50%      | 17%  | 0%       | 33%    |
| Oligodendriglioma                                | 28         | 7                            | 86%      | 0%   | 14%      | 0%     |
| Medulloblastoma                                  | 4          | 2                            | 100%     | 0%   | 0%       | 0%     |
| Ependymoma                                       | 10         | 1                            | 100%     | 0%   | 0%       | 0%     |
| Soft-tissue tumors                               |            |                              |          |      |          |        |
| Chondrosarcoma                                   | 5          | 2                            | 50%      | 0%   | 0%       | 50%    |
| Angiosarcoma                                      | 7          | 5                            | 60%      | 0%   | 20%      | 20%    |
| Liposarcoma                                      | 16         | 14                           | 86%      | 0%   | 7%       | 7%     |
| Neurofibroma                                     | 60         | 21                           | 100%     | 0%   | 0%       | 0%     |
| Desmoid tumor                                    | 9          | 9                            | 100%     | 0%   | 0%       | 0%     |
| Synovia, giant cell carcinoma                    | 40         | 9                            | 100%     | 0%   | 0%       | 0%     |
| Hemangiopericytoma                               | 7          | 5                            | 100%     | 0%   | 0%       | 0%     |
| Lymphatic tumors                                 |            |                              |          |      |          |        |
| Lymphoma, Hodgkin                                | 43         | 10                           | 10%      | 0%   | 90%      | 0%     |
| Thymoma                                          | 57         | 43                           | 98%      | 0%   | 0%       | 2%     |

<sup>a</sup>Analyzable refers to tumor cells containing spots on the tissue microarray.
found in breast cancers of no special type (7%) and clear cell renal cell cancers (4%). Examples of immunostaining of IMP3 positive and negative tissues are presented in Fig. 1.

The tumor types where IMP3 protein expression could never be detected included dermatofibrosarcomas of the skin (0 out of 4), subtypes of breast cancers (including lobular, mucinous, tubular cancers and phylloid tumors, 0 out of 11-23), leiomyomas (0 out of 20), stromal sarcomas (0 out of 2), GIST (0 out of 40), parotid adenomas (0 out of 30), neuroendocrine pancreatic cancers (0 out of 5), prostate cancers (0 out of 44), pheochromocytomas (0 out of 48), medulloblastomas (0 out of 2), ependymomas (0 out of 1), neurofibromas (0 out of 21), desmoid tumors (0 out of 9), synovial giant cell carcinomas (0 out of 9) and hemangiopericytomas (0 out of 5) and. However, the number of examined cases of several of these tumor types was low. These data therefore do not rule out that IMP3 expression can sometimes also occur in these tumor types.

Tumor type-specific prognostic TMAs. Expression data were available for 639 out of 697 (91.6%) urinary bladder cancers, 1204 out of 1711 (70.4%) colon cancers, 216 out of 343 (63%) adenocarcinomas of the esophagus, 170 out of 251 (67.7%) squamous cell carcinomas of the esophagus, 641 out of 763 (84%) lung cancers, 280 out of 358 (78.2%) pancreas carcinomas, and 204 out of 230 (88.7%) stomach cancers on the prognostic TMAs.

IMP3 positivity was found in 21.9% of urinary bladder cancers (strong: 7.4%, moderate: 8.1%, weak: 6.4%), 63.4% of colon tumors (strong: 36%, moderate: 16.6%, weak: 10.7%), 74.1% of esophageal adenocarcinomas (strong: 50.5%, moderate: 11.1%, weak: 12.5%), 60.6% of esophageal squamous cell cancers (strong: 41.8%, moderate: 8.2%, weak: 10.6%), 63.2% of lung cancers (strong: 47.1%, moderate: 11.4%, weak: 4.7%), 48.9% of pancreatic cancers (strong: 8.2%, moderate: 10.7%, weak: 30%), and 44.9% of stomach cancers (strong: 24%, moderate: 10.8%, weak: 20.1%).

Significant associations were found between IMP3 and advanced stage and grade in urinary bladder cancers (P<0.0001 each, Fig. 2A), in high grade and metastatic phenotype in esophageal adenocarcinomas (P≤0.0025, Fig. 2B), in a squamous cell phenotype in lung cancers (P<0.0001, Fig. 2C), and in shortened survival in adenocarcinomas of the lungs (P=0.0175, Fig. 2D), in stomach (P=0.0032, Fig. 2E) and in pancreatic cancers (P=0.0304, Fig. 2F). No significant associations between IMP3 expression levels and patient prognosis were observed in urinary bladder cancers, squamous cell lung cancers and squamous cell esophageal cancers.

Discussion

The results of our study provide a comprehensive catalogue of IMP3 expression across a large variety of human types of cancer and subtypes. Our findings demonstrated that high levels of IMP3 protein expression were found in the vast majority of the analyzed types of cancer and underscored its considerable general importance in tumor biology. The novelty of this study is that staining was performed with a single antibody, in 1 laboratory on a large panel of different tumor entities on a single microarray.

The frequency of IMP3 expression in individual types of cancer is well in the range of that reported from previous research (Fig. 3), which corroborates the validity of our results. For example, virtually all analyzed testicular cancers; teratomas, Hodgkin's lymphomas and Merkel cell cancers of the skin were IMP3-positive under the experimental conditions selected for this study, which fits well with the 85-99% positivity reported in the literature (4,34-36). In contrast, and in concordance with previous research, tumor types largely lacking detectable IMP3 expression included breast cancers of no special type, gastrointestinal stromal tumors, desmoid tumors, benign naevi or leiomyomas, which all have been described as predominantly IMP3-negative before (21,37,38). More variable findings with respect to published data were made in tumor types with intermediate IMP3-positivity, such as hepatocellular carcinomas (53-68% in the literature; 40% in our study) or colon cancers (15-65% in the literature; 47% in our study). It is obvious, that different antibodies and immunohistochemistry protocols, scoring criteria and the comparatively small number of samples (usually <50 per tumor category in our study) account for these differences.

There were 14 tumor types that were newly identified as having occasional IMP3 protein overexpression in this study. These included many important types of cancer such as squamous cell cancers of the vagina and vulva, medullary breast

Figure 1. Examples of IMP3 staining in a case of (A) normal kidney tissue, (B) placenta, (C) seminoma, (D) non-seminoma (E) pancreatic cancer and (F) Hodgkin lymphoma.
and thyroid cancers, pharyngeal carcinomas, various sarcomas (including chondro-, angio- and liposarcomas), oncocytomas, as well as some types of neuronal cancers (e.g. paragangliomas and oligodendrogliomas). These findings further add to the growing list of IMP3-expressing types of cancer and emphasize the general role of IMP3 as a marker for malignant growth of tumors arising from epithelial, mesenchymal and neuronal tissues.

Since IMP3 is often referred to as a marker for distinguishing between benign and malignant lesions (39–43), it was of interest to also find at least occasional expression in a few individual cells of glandular epithelium, lymphatic tissues and placenta, which was in accordance to earlier studies demonstrating that IMP3 was ubiquitously expressed in early developmental stages of human tissues but also in adult placenta (44,45). In addition, we also found IMP3 expression in benign lesions such as Warthin's tumors, schwannomas, colon adenomas and basal cell adenomas. Such findings are often made in studies including multiple types of tumors and demonstrate that the specificity of molecular markers are often overestimated in initial studies including only a limited number of different samples. For example, IMP3 has been suggested to aid in the diagnosis of melanoma, leiomyosarcoma, HCC, papillary thyroid carcinoma, and follicular thyroid carcinomas, but it is not a sensitive marker for these tumors as lack of IMP3 expression in these tumors cannot exclude a malignant phenotype (reviewed in ref. 1).
In addition to analyzing the molecular epidemiology of IMP3 expression, we took advantage of various pre-existing tumor type-specific prognostic TMAs for evaluation of the clinical significance of IMP3 expression in several tumor types. Urinary bladder, colon, esophageal, lung, pancreatic and stomach cancer were selected for follow-up studies because IMP3 was frequently positive in these tumor types and large TMAs were available. Significant associations between IMP3 expression and tumor phenotype as well as patient prognosis in our study further added to the knowledge on the clinical impact of IMP3 in these tumor types, which have been only studied in comparatively small cohorts of usually less than 100 cancer samples thus far. For example, the strong associations between IMP3 expression and advanced stage and grade in urinary bladder cancers and esophageal adenocarcinomas, or a squamous cell phenotype in lung cancers are in line with previous work on 76-384 cancers of the urinary bladder (23,24), 147 esophageal cancers (46) and 89-224 lung cancers (reviewed in refs. 47,48). Furthermore, the adverse prognostic impact of IMP3 expression in lung adenocarcinomas, pancreatic cancers and stomach cancers in our study were supported by previous studies on 40-190 patients in...
these types of cancer (10,11,48-50). In addition a recent meta-analysis revealed a hazard ratio of 2.08 for decreased survival in solid tumors expressing high levels of IMP3 (51).

Our analysis provides a comprehensive overview on IMP3 protein expression in neoplastic human tissues. Tissue microarrays are an ideal tool to massively accelerate characterization of novel biomarkers. The use of TMAs to jointly screen many different tumor types for molecular alterations of interest is an obvious application of this technique. In earlier studies we had used multi-tumor TMAs for the evaluation of cyclin E (52), calretinin (53), KIT (54), ERG (55) or copy number changes of 17q23 (56). Others have used comparable TMAs to evaluate SPANX-B (57), SIL (58), NOX1 (59), COX2, MMP2, or MMP9 (60).

It is a distinct advantage of the TMA technique that all tissues are analyzed under maximally standardized conditions. While automated immunostainers, despite some remaining day-to-day variability, can provide good standardization of the staining process, TMAs enable a control of several additional important parameters affecting immunostaining. For example, TMAs overcome the issue of slide ageing and decreased immunoreactivity (61) that can become a serious problem in conventional large studies where tissue sections are often stored over a longer period of time prior to analysis, because all tissue samples in a TMA can be easily sectioned and stained within one day.

In summary, the results of our study show that IMP3 expression is a common feature of most human solid cancer types, but may also be observed in benign lesions. Strong IMP3 expression is often linked to adverse tumor features.

Acknowledgements

We would like to thank Christina Koop, Julia Schumann, Sünje Seekamp, and Inge Brandt for excellent technical assistance.

References

1. Gong Y, Woda BA and Jiang Z: Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol 21: 191-200, 2014.
2. Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J and Nielsen FC: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25: 1456-1468, 2006.
3. Xu H, Bourne PA, Spaulding BO and Wang HL: High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 38: 555-563, 2007.
4. Goodman S, Zhang L, Cheng L and Jiang Z: Differential expression of IMP3 between male and female mature teratomas - immunohistochemical evidence of malignant nature. Histopathology 65: 483-489, 2014.
5. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, et al: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16: 3499-3506, 2009.
6. Lok T, Chen L, Lin F and Wang HL: Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol 45: 394-400, 2014.
7. Damasceno EA, Carneiro FP, Magalhães AV, Carneiro MV, Takano GH, Vianna LM, Seidler HB, Castro TM, Muniz-Junqueira MI, Amorim RF, et al: IMP3 expression in gastric cancer: Association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol 140: 2163-2168, 2014.
8. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48: 1118-1127, 2008.
9. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL and Kwon ED: Oncofetal protein IMP3: A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112: 2676-2682, 2008.
10. Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, Fu B, Zhou X and Zhao T: IMP3 predicts invasion and prognosis in human adenocarcinoma. Lung 194: 133-146, 2016.
11. Schaeffer DF, Owen DR, Lim HJ, Buczowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10: 59, 2010.
12. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Heich CC, Li C, Chen W, Duan HO, McDougall S, et al: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: A retrospective study. Lancet Oncol 7: 556-564, 2006.
13. Tossi Yildirim H and Sentürk N: Analysis of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg 28: 128-133, 2012.
14. Chromeceki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, et al: Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU Int 110: 63-68, 2012.
15. Ikenberg K, Fritzsche FR, Zuerzer-Haerdi U, Hofmann I, Hermanns T, Seiffert H, Müntener M, Provenzano M, Sülser T, Behnke S, et al: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 10: 341, 2010.
16. Szarvas T, Tschirdevan A, Niedworok C, Kramer G, Sevenco S, Reis H, Shariat SF, Rübben H and vom Dorp F: Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer 135: 1396-1404, 2009.
17. Kulaçoğlu S and Erkılıç G: IMP3 expression in benign and malignant thyroid tumors and hyperplastic nodules. Balkan Med J 32: 30-37, 2015.
18. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R and Khan A: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol 20: 149-157, 2009.
19. Torukoglu A, Yalınçin N, Avcı A, Çakalaçaoğlu F, Tayylaji G, Akin F, Haycianlı M and Özden A: Significance of IMP3, nucleophosmin, and Ki-67 expression in papillary thyroid carcinoma. Int J Surg Pathol 23: 5-12, 2015.
20. Jin L, Seys AR, Zhang S, Erickson-Johnson MR, ROTH CW, Evers BK, Oliveira AM and Lloyd RV: Diagnostic utility of IMP3 expression in thyroid neoplasms: A quantitative RT-PCR study. Diagn Mol Pathol 19: 63-69, 2010.
21. Yamamoto H, Arakaki K, Morimitsu K, Zaitsu Y, Fujita A, Kohashi K, Hirahashi M, Motoshita J, Oshiro Y and Oda Y: Insulin-like growth factor II messenger RNA-binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMJ Cancer 10: 341, 2010.
22. Corneko J, Shi M and Jiang Z: Oncofetal protein IMP3: A useful diagnostic biomarker for leiomyosarcoma. Hum Pathol 43: 1567-1572, 2012.
23. Lee DJ, Xylinas E, Riekien M, Khani F, Klatte T, Wood C, Karam JA, Weizer AZ, Raman JD, Remzi M, et al: Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. BJU Int 112: 379-385, 2013.
24. Xylinas E, Cha EK, Khani F, Klint LA, Riekien M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zeribib M, et al: Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J Urol 191: 830-841, 2014.
25. Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bifulfamante G, Ricca D, Fiore S, Bosari S and Ferrero S: The oncofetal protein IMP3: A useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. J Thorac Oncol 9: 1656-1661, 2014.
26. Chang S, Oh MH, Ji SY, Han J, Kim TJ, Eom M, Kwon KY, Ha SY, Choi YD, Lee CH, et al: Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int 64: 607-612, 2014.
37. Pryor JG, Simon RA, Bourne PA, Spaulding BO, Scott GA, Hammer NA, Hansen T, Byskov AG, Rajpert-de Meyts E, Tang H, Wei Q, Ge J, Jian W, Liu J, Zhong L, Fu B and Zhao T: Chokoeva AA, Ananiev J, Wollina U, Tana C, Lotti T, Cardoso JC, Ikeda K, Tate G, Suzuki T, Kitamura T and Mitsuya T: IMP3/IMP91 protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int 110: E308-E317, 2012.

38. Hottis-Hosey JJ and Xu H: Intrinsic-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 87: 24-29, 2012.

39. Wang L, Li HG, Xia ZS, Lu J and Peng TS: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: A retrospective study. Chin Med J (Engl) 123: 3554-3558, 2010.

40. Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, Shindo K, Fujino M, Tanaka M and Oda Y: Intrinsic-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm. Hum Pathol 44: 1714-1721, 2013.

41. Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L, Chen J and Zhang X: Prognostic value of high IMP3 expression in solid tumors: A meta-analysis. Onco Targets Ther 10: 2849-2863, 2017.

42. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilker S, Seelig S, Kononen J, Mihatsch MJ, Dirnhoffer S, et al: Cyclin E overexpression and amplification in human tumours. J Pathol 200: 375-382, 2003.

43. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ and Sauter G: Calretinin expression in human normal and neoplastic tissues: A tissue microarray analysis on 5233 tissue samples. Hum Pathol 34: 994-1000, 2003.

44. Went PT, Dirnhoffer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, et al: Prevalence of KIT expression in human tumours. J Clin Oncol 22: 4514-4522, 2004.

45. Minner S, Luebke AM, Kluh M, Bokemeyer C, Jancicke F, Izbicki JR and Bockhorn M: IMP3 distinguishes IMP3-negative gastric cancer from non-malignant lesions. J Clin Pathol 65: 1433-1437, 2012.

46. Lu D, Vohra P, Chu PG, Woda B, Rock KL and Jiang Z: A oncoprotein IMP3: A new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol 33: 521-525, 2009.

47. Szarvas T, von DL, Nielson FC, Metcalf S, Melchior-Becker A, Fischer JW, Singer BB, Reis H, Bankalvi A, Schmid KW, Romsics I, et al: High-insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int 110: E308-E317, 2012.

48. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and Gress TM: Expression of the highly conserved RNA binding protein KOC (karyopherin subunit beta 1) is restricted to mesothelial proliferations. Mech Dev 88: 95-99, 1999.
63. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE and Jianger Z: The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32: 304-315, 2008.

64. Yi X and Zheng W: Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol 20: 20-25, 2008.

65. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jianger Z, Lu D, Xu B, Dresser K, Lutman CV, et al: Expression of a novel oncofetal mRNA-binding protein 3 (IMP3) in endometrial carcinomas: Diagnostic significance and clinicopathologic correlations. Mod Pathol 20: 1263-1268, 2007.

66. Kazeminezhad B, Mirafsharieh SA, Dinnyari K, Azizi D and Feng W, Zhou Z, Peters JH, Khoury T, Zhai Q, Wei Q, Truong CD, Elshafey MR, Ahmed RA, Mourad MI and Gaballah ET: The oncofetal protein IMP3: A novel biomarker for adenocarcinoma of the gallbladder. Am J Surg Pathol 35: 873-877, 2011.

67. Minato H, Kurose N, Fukushima M, Nojima T, Usuda K, et al: Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in human esophageal adenocarcinoma and its precursor lesions. Arch Pathol Lab Med 135: 1024-1031, 2011.

68. He Y, Li L, Jianger W, Wang DQ, Xu L, Huang Q, Zhang Y and Yang KK: Expression of the insulin-like growth factor-II mRNA-binding protein 3 (IMP3) and carcinoembryonic antigen (CEA) in mucinous minimal designation adenocarcinoma. Pathol Res Pract 207: 295-298, 2011.

69. Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Lutman CV, et al: Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol 35: 183-187, 2011.

70. Lin L, Zhang J, Wang Y, Zheng L, Lin Z and Cai Y: Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and analysis of prognosis in the patients with lung squamous cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Zai Zhi 29: 694-697, 2013 (In Chinese).

71. Beljan Perak R, Durdev MG, Capkun V, Ivecic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 7: 165, 2012.

72. Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL and Xu H: IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 41: 477-484, 2010.

73. Chen ST, Jeng YM, Chang CC, Chang HH, Huang MC, Juan HF, Hsu CH, Lee H, Liao YF, Lee YL, et al: Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Cancer Sci 102: 2191-2198, 2011.

74. Takata A, Takiguchi S, Okada K, Takahashi T and Kurokawa Y: Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and its precursor lesions. Arch Pathol Lab Med 135: 1024-1031, 2011.

75. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston JL and et al: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience 2: 607-614, 2015.

76. Schroeder K, Yamamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, et al: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is correlated with p16(INK4a) expression. Mod Pathol 20: 242-247, 2007.

77. Shantha Kumaraa H, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordone-Cardo C, et al: Expression of the cancer testis antigen IGF2BP2 in colorectal cancers; IGF2BP2 holds promise as a specific immunotherapy target. Oncoscience 2: 607-614, 2015.

78. Liu W, Wang P, Li Z, Xu W, Dai L, Wang K and Zhang J: Evaluation of tumour-associated antigen (TAA) miniaarray in immunodiagnosis of colon cancer. Scand J Immunol 69: 57-63, 2009.

79. Barton VN, Donson AM, Birks DK, Kleinschmidt-DeMasters BK, Handler MH, Foreman NK and Rush SZ: Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma. J Neuropathol Exp Neurol 72: 442-449, 2013.

80. Bellesza G, Prosperi E, Del Sordo R, Coleta R, Rulli A and Sidoni A: IMP3 is strongly expressed in malignant phyllodes tumors of the breast: An immunohistochemical study. Int J Surg Pathol 24: 37-42, 2016.

81. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL and Khan A: IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40: 1528-1533, 2009.

82. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z and kwon Ed: External validation of IMP3 expression with p16(INK4a) expression. Mod Pathol 20: 295-298, 2011.

83. Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J, et al: IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 140: 883-893, 2014.

84. Su H, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J, et al: IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 22: 658-662, 2014.

85. Elshafey MR, Ahmed RA, Mourad MI and Gaballah ET: The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucopidermoid carcinoma of salivary glands. Cancer Biol Med 13: 286-295, 2016.

86. Ismerim AB, Ferreira SV, Lessa AM, Pereira Júnior AS, Gurgel CA, Coutinho-Camilo CM, Soares FA, Vilas-Bôas DS, Vidal MT and Santos JN: Insulin-like growth factor ii messenger RNA-binding protein 3 in salivary gland tumors. Appl Immunohistochem Mol Morphol 24: 422-426, 2016.

87. Chisté M, Alexis J and Recine M: IMP3 expression in serous tumors of the ovary. Appl Immunohistochem Mol Morphol 22: 658-662, 2014.

88. Yu L, Xu H, Wasco MJ, Bourne PA and Ma L: IMP-3 expression in melanocytic lesions. J Cutan Pathol 37: 316-322, 2010.

89. Elshafey MR, Ahmed RA, Mourad MI and Gaballah ET: The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucopidermoid carcinoma of salivary glands. Cancer Biol Med 13: 286-295, 2016.